Cargando…

Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats

As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies and other new formats, represent a key component in advancing antibody therapy. When designing new formats, a targeted modulation of pairing preferences is key. Sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Quintero, Monica L., Quoika, Patrick K., Wedl, Florian S., Seidler, Clarissa A., Kroell, Katharina B., Loeffler, Johannes R., Pomarici, Nancy D., Hoerschinger, Valentin J., Bujotzek, Alexander, Georges, Guy, Kettenberger, Hubert, Liedl, Klaus R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826573/
https://www.ncbi.nlm.nih.gov/pubmed/35155578
http://dx.doi.org/10.3389/fmolb.2022.812750
_version_ 1784647455548112896
author Fernández-Quintero, Monica L.
Quoika, Patrick K.
Wedl, Florian S.
Seidler, Clarissa A.
Kroell, Katharina B.
Loeffler, Johannes R.
Pomarici, Nancy D.
Hoerschinger, Valentin J.
Bujotzek, Alexander
Georges, Guy
Kettenberger, Hubert
Liedl, Klaus R.
author_facet Fernández-Quintero, Monica L.
Quoika, Patrick K.
Wedl, Florian S.
Seidler, Clarissa A.
Kroell, Katharina B.
Loeffler, Johannes R.
Pomarici, Nancy D.
Hoerschinger, Valentin J.
Bujotzek, Alexander
Georges, Guy
Kettenberger, Hubert
Liedl, Klaus R.
author_sort Fernández-Quintero, Monica L.
collection PubMed
description As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies and other new formats, represent a key component in advancing antibody therapy. When designing new formats, a targeted modulation of pairing preferences is key. Several existing approaches are successful, but expanding the repertoire of design possibilities would be desirable. Cognate immunoglobulin G antibodies depend on homodimerization of the fragment crystallizable regions of two identical heavy chains. By modifying the dimeric interface of the third constant domain (C(H)3-C(H)3), with different mutations on each domain, the engineered Fc fragments form rather heterodimers than homodimers. The first constant domain (C(H)1-C(L)) shares a very similar fold and interdomain orientation with the C(H)3-C(H)3 dimer. Thus, numerous well-established design efforts for C(H)3-C(H)3 interfaces, have also been applied to C(H)1-C(L) dimers to reduce the number of mispairings in the Fabs. Given the high structural similarity of the C(H)3-C(H)3 and C(H)1-C(L) domains we want to identify additional opportunities in comparing the differences and overlapping interaction profiles. Our vision is to facilitate a toolkit that allows for the interchangeable usage of different design tools from crosslinking the knowledge between these two interface types. As a starting point, here, we use classical molecular dynamics simulations to identify differences of the C(H)3-C(H)3 and C(H)1-C(L) interfaces and already find unexpected features of these interfaces shedding new light on possible design variations. Apart from identifying clear differences between the similar C(H)3-C(H)3 and C(H)1-C(L) dimers, we structurally characterize the effects of point-mutations in the C(H)3-C(H)3 interface on the respective dynamics and interface interaction patterns. Thus, this study has broad implications in the field of antibody engineering as it provides a structural and mechanistical understanding of antibody interfaces and thereby presents a crucial aspect for the design of bispecific antibodies.
format Online
Article
Text
id pubmed-8826573
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88265732022-02-10 Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats Fernández-Quintero, Monica L. Quoika, Patrick K. Wedl, Florian S. Seidler, Clarissa A. Kroell, Katharina B. Loeffler, Johannes R. Pomarici, Nancy D. Hoerschinger, Valentin J. Bujotzek, Alexander Georges, Guy Kettenberger, Hubert Liedl, Klaus R. Front Mol Biosci Molecular Biosciences As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies and other new formats, represent a key component in advancing antibody therapy. When designing new formats, a targeted modulation of pairing preferences is key. Several existing approaches are successful, but expanding the repertoire of design possibilities would be desirable. Cognate immunoglobulin G antibodies depend on homodimerization of the fragment crystallizable regions of two identical heavy chains. By modifying the dimeric interface of the third constant domain (C(H)3-C(H)3), with different mutations on each domain, the engineered Fc fragments form rather heterodimers than homodimers. The first constant domain (C(H)1-C(L)) shares a very similar fold and interdomain orientation with the C(H)3-C(H)3 dimer. Thus, numerous well-established design efforts for C(H)3-C(H)3 interfaces, have also been applied to C(H)1-C(L) dimers to reduce the number of mispairings in the Fabs. Given the high structural similarity of the C(H)3-C(H)3 and C(H)1-C(L) domains we want to identify additional opportunities in comparing the differences and overlapping interaction profiles. Our vision is to facilitate a toolkit that allows for the interchangeable usage of different design tools from crosslinking the knowledge between these two interface types. As a starting point, here, we use classical molecular dynamics simulations to identify differences of the C(H)3-C(H)3 and C(H)1-C(L) interfaces and already find unexpected features of these interfaces shedding new light on possible design variations. Apart from identifying clear differences between the similar C(H)3-C(H)3 and C(H)1-C(L) dimers, we structurally characterize the effects of point-mutations in the C(H)3-C(H)3 interface on the respective dynamics and interface interaction patterns. Thus, this study has broad implications in the field of antibody engineering as it provides a structural and mechanistical understanding of antibody interfaces and thereby presents a crucial aspect for the design of bispecific antibodies. Frontiers Media S.A. 2022-01-26 /pmc/articles/PMC8826573/ /pubmed/35155578 http://dx.doi.org/10.3389/fmolb.2022.812750 Text en Copyright © 2022 Fernández-Quintero, Quoika, Wedl, Seidler, Kroell, Loeffler, Pomarici, Hoerschinger, Bujotzek, Georges, Kettenberger and Liedl. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Fernández-Quintero, Monica L.
Quoika, Patrick K.
Wedl, Florian S.
Seidler, Clarissa A.
Kroell, Katharina B.
Loeffler, Johannes R.
Pomarici, Nancy D.
Hoerschinger, Valentin J.
Bujotzek, Alexander
Georges, Guy
Kettenberger, Hubert
Liedl, Klaus R.
Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
title Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
title_full Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
title_fullStr Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
title_full_unstemmed Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
title_short Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
title_sort comparing antibody interfaces to inform rational design of new antibody formats
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826573/
https://www.ncbi.nlm.nih.gov/pubmed/35155578
http://dx.doi.org/10.3389/fmolb.2022.812750
work_keys_str_mv AT fernandezquinteromonical comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT quoikapatrickk comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT wedlflorians comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT seidlerclarissaa comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT kroellkatharinab comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT loefflerjohannesr comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT pomaricinancyd comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT hoerschingervalentinj comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT bujotzekalexander comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT georgesguy comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT kettenbergerhubert comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats
AT liedlklausr comparingantibodyinterfacestoinformrationaldesignofnewantibodyformats